Investor Presentation: First Nine Months of 2020
21
Investor presentation First nine months of 2020
Novo Nordisk's opportunity is in the large unmet needs across all
therapy areas in scope
DIABETES
-463 million
-6%
~650 million
OBESITY
-2%
Novo Nordisk®
HAEMOPHILIA
OTHER SERIOUS CHRONIC
DISEASES
~0.5 million
-25%
People with
diabetes
People in good
control
People with
obesity
People medically
treated
People with
haemophilia
People being
treated
80% of diagnosed NASH
patients are obese
and 35% have T2DM
70% of diabetes patients die
from atherosclerotic CVD
40% of patients hospitalised
for heart failure are diabetic
Gro
~50% of the total CKD
population suffers from
diabetic nephropathy
NASH: Non-alcoholic steatohepatitis, T2DM: Type 2 diabetes mellitus, CVD: Cardiovascular disease, CKD: Chronic kidney disease
Source: International Diabetes Federation; Diabetes Atlas 9th Edition 2019, IQVIA MIDAS 2017, World Federation of Haemophilia - Annual survey 2018; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017; Heart Disease
and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilising ultrasound and liver biopsy, 2011; Addressing the global burden of chronic
kidney disease through clinical and translational research, 2014View entire presentation